+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of HIV-associated dysmorphia/dysmetabolic syndrome with or without lipodystrophy

Treatment of HIV-associated dysmorphia/dysmetabolic syndrome with or without lipodystrophy

Official Gazette of the United States Patent & Trademark Office Patents 1279(4), Feb 24

Pathological regional adipose tissue accumulation associated with HIV-associated dysmorphic/dysmetabolic syndrome (HADDS) which may occur with or without subcutaneous adipose tissue lipodystrophy (and which is also described as HIV-associated adipose redistribution syndrome or HARS and other specific medical terms), is treated by administering an effective amount of human growth hormone or other substance which binds to and initiates signalling of the hGH receptor. Alternatively, a substance which stimulates production of endogenous hGH, such as human growth hormone releasing hormone, may be administered. HADDS and related syndromes include abnormal adipose tissue accumulation in the visceral, submandibular, supraclavicular, pectoral, mammary and/or dorsocervical (buffalo hump) area, and/or with subcutaneous lipomas, with or without associated metabolic or other physiologic abnormalities.

(PDF emailed within 1 workday: $29.90)

Accession: 035980460

Download citation: RISBibTeXText

Related references

Dysmetabolic syndrome in a man with a novel mutation of the aromatase gene: effects of testosterone, alendronate, and estradiol treatment. Journal of Clinical Endocrinology and Metabolism 89(1): 61-70, 2004

Berardinelli lipodystrophy: (Generalized lipodystrophy syndrome): A case report and review of the literature. Annals of Saudi Medicine 12(4): 400-402, 1992

Evolving perspectives on HIV-associated lipodystrophy syndrome: moving from lipodystrophy to non-infectious HIV co-morbidities. Journal of Antimicrobial ChemoTherapy 64(3): 437-440, 2009

Viscero cranial dysmorphia and dysmorphia of the odonto parodontal system in acromegaly. Revista de Chirurgie Oncologie Radiologie O R L Oftalmologie Stomatologie Seria Stomatologie 31(3): 185-192, 1984

Dysmetabolic symptomatic arterial hypertension and dysmetabolic disease. Klinicheskaia Meditsina 87(8): 67-71, 2009

L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome. HIV Medicine 2(1): 59-60, 2001

Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. Aids Reviews 15(3): 171-180, 2014

Opitz-trigonocephaly syndrome--a characteristic dysmorphia-retardation syndrome of unclear origin. Klinische Padiatrie 204(3): 171-173, 1992

Mental retardation, ataxia, seizures, dysmorphia, and hydrocephaly in two sibs. Angelman syndrome or new syndrome. Genetic Counseling 4(2): 153-156, 1993

Claude Bernard syndrome, so-called Horner's syndrome, and heterochromia with brachio-vertebral dysmorphia caused by osteomyelitis. Bulletin des Societes D'ophtalmologie de France 68(4): 501-502, 1968

HIV-associated lipodystrophy syndrome: LioN-HAART cohort: (lipodystrophy in patients on nucleoside-based HAART). Highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 31(2): 253-255, 2002

Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin. Journal of Endocrinological Investigation 37(6): 533-539, 2015

Control and treatment of HIV-associated lipodystrophy syndrome and related metabolic complications. Ugeskrift for Laeger 165(44): 4218-4220, 2003

Evaluation of safety and efficacy of rosiglitazone in the treatment of HIV-associated lipodystrophy syndrome. Infection 34(2): 55-61, 2006

Lipodystrophy syndrome of patients infected by HIV receiving antiretroviral treatment. Journees Annuelles de Diabetologie de L'hotel-Dieu: 111-123, 2003